Ovarian Cancer Clinical Trial
Official title:
A Phase 1, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02390 in Participants With Select Advanced Malignancies
Verified date | November 2021 |
Source | Incyte Corporation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with select advanced malignancies.
Status | Completed |
Enrollment | 40 |
Est. completion date | August 18, 2021 |
Est. primary completion date | August 18, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Participants with locally advanced or metastatic tumors who are not eligible for any available therapy likely to convey clinical benefit (locally advanced disease must not be amenable to resection with curative intent). - Participants who have disease progression after treatment with available therapies that are known to confer clinical benefit or who are intolerant to treatment. - Willingness and ability to safely undergo pretreatment and on-treatment tumor biopsies (core or excisional). - Eastern Cooperative Oncology Group performance status 0 or 1. - Willingness to avoid pregnancy or fathering children based on protocol-defined criteria. Exclusion Criteria: - Laboratory values at screening outside the protocol-defined ranges. - Administration of colony-stimulating factors within 14 days before Study Day 1. - Receipt of anticancer medications or investigational drugs within protocol-defined intervals before the first administration of study drug. - Receipt of a live vaccine within 30 days of planned start of study drug. Note: Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox/zoster, yellow fever, rabies, Bacillus Calmette-Guérin, and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines are live-attenuated vaccines and are not allowed. - Active autoimmune disease that required systemic treatment in the past (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). - Known active central nervous system metastases and/or carcinomatous meningitis. - Known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 2 years of study entry with the exception of cured basal cell or squamous cell carcinoma of the skin, superficial bladder cancer, prostate intraepithelial neoplasm, carcinoma in situ of the cervix, or other noninvasive or indolent malignancy, or cancers from which the participant has been disease-free for > 1 year, after treatment with curative intent. - Evidence of active, noninfectious pneumonitis or history of interstitial lung disease. - Active infection requiring systemic therapy. - Evidence of active HBV or HCV infection. - Known history of HIV (HIV 1/2 antibodies). - Known allergy or reaction to any component of study drug or formulation components. - Prior treatment with an anti-TIM-3 antibody for any indication. |
Country | Name | City | State |
---|---|---|---|
United States | Hackensack Medical Center | Hackensack | New Jersey |
United States | Carolina BioOncology | Huntsville | North Carolina |
United States | University of Mississippi | Jackson | Mississippi |
United States | The Angeles Clinical and Research Institute | Los Angeles | California |
Lead Sponsor | Collaborator |
---|---|
Incyte Corporation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of treatment-emergent adverse events | Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug. | Up to 12 months | |
Primary | Maximum tolerated dose or pharmacologically active dose (PAD) of INCAGN02390 (Part 1 only) | PAD defined as a dose that achieves a level of receptor occupancy considered to be biologically active. | Up to approximately 1 month | |
Secondary | Cmax of INCAGN02390 | Maximum observed plasma or serum concentration. | Up to 12 months | |
Secondary | Tmax of INCAGN02390 | Time to maximum concentration. | Up to 12 months | |
Secondary | Cmin of INCAGN02390 | Minimum observed plasma or serum concentration over the dose interval. | Up to 12 months | |
Secondary | AUC0-t of INCAGN02390 | Area under the plasma or serum concentration-time curve from time = 0 to the last measurable concentration at time = t. | Up to 12 months | |
Secondary | Objective response rate | Defined as the percentage of participants having complete response (CR) or partial response (PR) determined by investigator assessment of radiographic disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. | Up to 12 months | |
Secondary | Duration of response | Defined as time from earliest date of disease response (CR or PR) until earliest date of disease progression (determined by investigator assessment of radiographic disease per RECIST v1.1) or death from any cause, if occurring sooner than progression. | Up to 12 months | |
Secondary | Disease control rate | Defined as percentage of participants having CR, PR, or stable disease as best on-study response. | Up to 12 months | |
Secondary | Progression-free survival | Defined as the time from date of first dose of study drug until the earliest date of disease progression (determined by investigator assessment of objective radiographic disease per RECIST v1.1) or death from any cause if occurring sooner than progression. | Up to 12 months | |
Secondary | Level of binding of INCAGN02390 to TIM-3 | Assessed from participant whole blood samples. | Up to approximately 3 months | |
Secondary | Immunogenicity of INCAGN02390 | Defined as the occurrence of specific ADA to INCAGN02390. | Up to 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Withdrawn |
NCT05201001 -
APX005M in Patients With Recurrent Ovarian Cancer
|
Phase 2 | |
Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156892 -
Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer
|
Phase 1 | |
Suspended |
NCT02432378 -
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
|
Phase 1/Phase 2 | |
Recruiting |
NCT04533763 -
Living WELL: A Web-Based Program for Ovarian Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT03371693 -
Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer
|
Phase 3 | |
Withdrawn |
NCT03032614 -
Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients
|
Phase 2 | |
Completed |
NCT02019524 -
Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients
|
Phase 1 | |
Completed |
NCT01936363 -
Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer
|
Phase 2 | |
Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
Active, not recruiting |
NCT04383210 -
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
|
Phase 2 | |
Terminated |
NCT04586335 -
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
|
Phase 1 | |
Terminated |
NCT03146663 -
NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer
|
Phase 2 |